Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
The World Health Organization estimates that 65 million people worldwide have moderate to severe COPD. COPD is a major cause of disability and is expected to become the leading cause of death globally within the next two decades. There is no cure for COPD. There are treatments available for doctors to prescribe, including treatments called maintenance therapies to help maintain regular breathing. However, even with the combination of therapies, some people still have COPD symptoms or experience COPD exacerbations, which can result in a hospital admission. Napa Research has a clinical research study aimed at reducing the occurrence of COPD exacerbations with the use of study medication.
Mode of administration:
A single inhaler- Inhaled corticosteroid (ICS) with either a LAMA (long-acting muscarinic antagonist, a LABA (long-acting beta-2 agonist) or both.
The study duration: 55 weeks
Participants will attend 13 study site visits and received 2 wellness check phone calls after study.
Compensation package includes:
$70 for screening
$70 for each visit to study site
All study medication, assessments and examinations are free to the participants.
Has the patient been diagnosed with COPD by a Pulmonologist or PCP? (YES/ NO)
Is the patient currently taking medication for COPD?
Has the patient had a COPD exacerbation in the past 12months?
Is the patient a current or ex-smoker?
Patient’s other medical conditions: